echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express delivery of refractory patients with a complete remission rate of more than 30%, and the phase 2 clinical results of the CD37-targeted ADC combination are positive

    Express delivery of refractory patients with a complete remission rate of more than 30%, and the phase 2 clinical results of the CD37-targeted ADC combination are positive

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎ WuXi AppTec content team editor June 14, 2021, Debiopharm announced its CD37 targeting antibody conjugate (ADC) naratuximab emtansine, combined with rituximab (anti-CD20 antibody), in the treatment of relapsed/refractory Positive results were obtained in the Phase 2 clinical trial of R/R diffuse large B-cell lymphoma (DLBCL)
    .

    The trial results showed that the combination therapy achieved a complete response rate (CRR) of 31.
    6% in R/R DLBCL patients who had received more than two previous treatments
    .

     The latest results presented at the European Hematology Association (EHA) annual meeting on June 12 showed that among refractory patients who have previously received more than two treatments, naratuximab emtansine combined with rituximab can be evaluated The objective response rate (ORR) in the patients (N=76) was 44.
    7%, and the CRR was 31.
    6%
    .

    The median duration of response (DoR) has not yet been reached.
    66% of responders have a DoR greater than 12 months, showing the durability of the effect
    .

    In terms of safety, the safety characteristics of the combination therapy are predictable and manageable, the rate of treatment discontinuation due to adverse events is low (8%), and the incidence of severe febrile neutropenia is low (4%)
    .

    Naratuximab emtansine is a potentially innovative method for the treatment of patients with B-cell malignancies
    .

    This ADC binds to CD37 with high affinity and specificity, and the carried load DM1 can hinder the cell proliferation pathway after being released in the cell, and then induce cell cycle arrest and apoptosis
    .

    In addition to DLBCL, it also shows good potential in the treatment of mantle cell lymphoma, follicular lymphoma, and acute myeloid leukemia
    .

    Image source: Bioconjugator, CC BY-SA 4.
    0 <https://creativecommons.
    org/licenses/by-sa/4.
    0>, via Wikimedia Commons In most countries around the world, NHL is listed as the 5th to 9th most common cancer In 2018, it is estimated that there will be more than 500,000 new cases
    .

    Although advances in NHL therapy have significantly improved the prognosis of patients, some patients still develop resistance to first-line and second-line therapies, or do not meet the requirements of stem cell transplantation therapy, which affects the survival of patients
    .

    The need to improve the prognosis of patients has led to the exploration of innovative treatment strategies, such as targeting the CD37 antigen on the basis of standard treatment methods
    .

    Diffuse large B-cell lymphoma is the most common aggressive NHL, accounting for 30-40% of all cases
    .

    Nearly half of the patients cannot be cured by first-line treatment, leaving a large number of patients at risk of worsening their condition
    .

    "We now see that this combination of targeting both CD37 and CD20 can address the unmet needs of DLBCL patients who have relapsed or did not respond to early treatment
    .

    " said Dr.
    Bertrand Ducrey, CEO of Debiopharm, "These promising results And good safety features will encourage us to further explore the potential benefits that this powerful ADC technology may bring to patients
    .

    "Reference: [1] Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies.
    Retrieved June 14, 2021, from https:// -antibody-drug-conjugate-shows-promising-phase-ii-results-for-the-treatment-of-b-cell-malignancies-301311534.
    html Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
    .

    If you need guidance on treatment plans, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.